Inhibition of exaggerated gastrointestinal glucagon responses in chronic pancreatitis by somatostatin.
Oral glucose administration caused an exaggerated release of cross-reacting gastrointestinal glucagon-like immunoreactivity (GLI) and a slight early rise in immunoreactive glucagon (IRG) concentration in patients with chronic pancreatitis, who have impaired insulin release. Intravenous administration of 200 microgram of somatostatin, followed by infusion of 200 microgram over 2 1/2 h, abolished the GLI and insulin responses, but did not change glucose tolerance. This contrasts with the relatively minor effects of somatostatin on GLI responses in control subjects where the clear deterioration in glucose tolerance may relate to inhibition of insulin release.
D000368:Aged; D002908:Chronic Disease; D005934:Glucagon / Q000097:blood* / Q000276:immunology; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000097:blood*; D013004:Somatostatin
D007328:Insulin; D013004:Somatostatin; D005934:Glucagon